Hematopoietic Stem Cell Transplantation Global Market Report 2024

The hematopoietic stem cell transplantation market has grown strongly in recent years. It will grow from $4.24 billion in 2023 to $4.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The expansion observed in the historical period can be attributed to factors such as the development of early transplantation techniques, limited indications and donor sources, advancements in conditioning regimens, the emergence of allogeneic transplants, and regulatory milestones in the field of hematopoietic stem cell transplantation.

The hematopoietic stem cell transplantation market is expected to see rapid growth in the next few years. It will grow to $6.82 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The anticipated growth in the forecast period can be attributed to expanded treatment indications, diversification of donor sources, the influence of personalized medicine and genomics, regulatory changes and updated guidelines, and increased market expansion and accessibility. Key trends expected in the forecast period encompass advancements in transplant techniques, a broader range of treatment indications, the emergence of cellular therapies, a more diverse donor pool, and the adoption of a precision medicine approach in hematopoietic stem cell transplantation.

The anticipated surge in the occurrence of blood cancer is set to drive the growth of the hematopoietic stem cell transplantation market. Blood cancers encompass a group of malignancies affecting the development and functioning of blood cells, including leukemia, lymphoma, and myeloma. Hematopoietic stem cell transplantation is a common treatment for these conditions, involving the replacement of stem cells and bone marrow cells damaged by the malignancy. These transplanted stem cells migrate to the bone marrow, initiating the production of new blood cells. In August 2022, Blood Cancer UK reported 41,000 identified blood cancer cases annually in the UK, making it the sixth most prevalent cancer. With an estimated 250,000 people affected in 2022, including over 500 children, the increased incidence of blood cancer drives the hematopoietic stem cell transplantation market.

The burgeoning aging population is expected to contribute to the growth of the hematopoietic stem cell transplantation market. The aging population, defined as individuals aged 65 and older, finds hematopoietic stem cell transplantation a viable treatment for various hematological disorders. As a notable example, the World Health Organization projected that globally, one in six people would be 60 or older by 2030, with the number doubling to 2.1 billion by 2050. In the UK, it is anticipated that by 2043, 24% of the total population (17.4 million people) will be seniors. Consequently, the expanding aging population propels the hematopoietic stem cell transplantation market.

Product approvals emerge as a prominent trend in the hematopoietic stem cell transplantation market, with major companies securing regulatory clearances to sustain their market positions. For instance, in April 2022, Ireland-based Priothera Ltd. received FDA clearance for an investigational new drug (IND) to initiate a Phase IIb/III research study with mocravimod in acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplant. Mocravimod, a synthetic sphingosine 1-phosphate receptor (S1PR) modulator, demonstrated safety and efficacy in earlier trials for various autoimmune diseases.

Major companies in the hematopoietic stem cell transplantation industry are adopting a strategic partnership approach to accelerate research and development through complementary strengths. In July 2021, US-based biotech company Vor Biopharma collaborated with Belgium-based Janssen Pharmaceutical to develop engineered hematopoietic stem cell transplants (eHSCTs) combined with a bi-specific antibody therapy for acute myeloid leukemia (AML). This partnership aims to broaden the application of eHSCT-based therapies to other cancers and blood disorders.

In August 2022, France-based Eurobio Scientific Group acquired Netherlands-based Genome Diagnostics B.V. for $132.3 million, enhancing Eurobio's commercial portfolio for evaluating compatibility in organ and marrow transplants, further solidifying its position in the hematopoietic stem cell transplantation market.

Major companies operating in the hematopoietic stem cell transplantation market report are Pluristem Therapeutics Inc., Lonza Group AG, Escape Therapeutics Inc., Regen Biopharma Inc., Bluebird Bio Inc., CellGenix GmbH, CBR Systems Inc., Merck KGaA, Cord Blood Corporation, Kiadis Pharma NV, Marker Therapeutics Inc., Taiga Biotechnologies Inc., Takeda Pharmaceutical Company Limited, Talaris Therapeutics Inc., ViaCord LLC, ScienCell Research Laboratories Inc., BiolineRx, Stemcell Technologies Inc., ThermoGenesis Holdings Inc., MEDIPOST Co. Ltd., Anterogen. Co. Ltd., Pharmicell Inc., NuVasive Inc., RTI Surgical Ltd., JCR Pharmaceuticals Co. Ltd., Holostem Terapie Avanzate Srl, Regrow Biosciences Pvt Ltd., Stempeutics Research Pvt Ltd., 3D Biomatrix, Worthington Biochemical.

North America was the largest region in the hematopoietic stem cell transplantation market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global hematopoietic stem cell transplantation market during the forecast period. The regions covered in the hematopoietic stem cell transplantation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hematopoietic stem cell transplantation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of cells used in hematopoietic stem cell transplantation are allogeneic and autologous. Allogeneic transplants involve stem cells obtained from a donor with a different genetic makeup than the recipient. This type of transplantation is applied to address conditions such as leukemia, lymphatic disorders, myeloma, and others. The applications include bone marrow transplants, peripheral blood stem cell transplants, and cord blood transplants. Hematopoietic stem cell transplantation is utilized by various end-users, including hospital pharmacies, retail pharmacies, and specialty clinics.

The hematopoietic stem cell transplantation market research report provides hematopoietic stem cell transplantation market statistics, including hematopoietic stem cell transplantation industry global market size, regional shares, competitors with a hematopoietic stem cell transplantation market share, detailed hematopoietic stem cell transplantation market segments, market trends and opportunities, and any further data you may need to thrive in the hematopoietic stem cell transplantation industry. This hematopoietic stem cell transplantation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hematopoietic stem cell transplantation (HSCT) market includes revenues earned by entities providing services such as medical evaluation, pre-transplant care, stem cell collection and processing, transplantation procedures, post-transplant care, supportive care, and long-term follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.